智飞生物控股子公司德谷门冬双胰岛素注射液完成Ⅲ期临床试验

Core Viewpoint - Chongqing Zhifei Biological Products Co., Ltd.'s subsidiary, Chongqing Chanan Biopharmaceutical Co., Ltd., has successfully completed the phase III clinical trial for CA508 injection, a dual insulin product for treating type 2 diabetes, demonstrating efficacy and safety comparable to the original drug [1][2]. Product Development Progress and Market Path - Following the completion of the phase III clinical trial, Chongqing Chanan Biopharmaceutical Co., Ltd. will submit a drug production registration application to the National Medical Products Administration, which must pass technical review and clinical site inspection before market approval [2]. - The successful development of CA508 injection signifies a significant breakthrough for Chongqing Chanan Biopharmaceutical Co., Ltd. in the diabetes treatment sector, with broad clinical application prospects [2]. Impact on Company Business Layout - Chongqing Zhifei Biological Products Co., Ltd. indicated that CA508 injection will not have a major short-term impact on overall company performance, but successful market approval could strengthen the company's treatment segment within its integrated "prevention & treatment" business layout [3]. - The strategic extension into therapeutic drugs, particularly in diabetes treatment, reflects the company's commitment to diversifying beyond its traditional vaccine business, laying a solid product foundation for long-term development [3].